Claudin-18.2 targeting by zolbetuximab: results of SPOTLIGHT in perspective

叶酸 奥沙利铂 内科学 养生 肿瘤科 癌症 指南 结直肠癌 医学 胃肠病学 病理
作者
Hanneke W.M. van Laarhoven,Sarah Derks
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10389): 1630-1631 被引量:9
标识
DOI:10.1016/s0140-6736(23)00732-8
摘要

Advances in biomarker-based targeted treatments have been slow for patients with stage IV gastro-oesophageal adenocarcinoma, with median overall survival for patients with human epidermal growth factor receptor 2 (HER2)-negative disease not exceeding a year. 1 Ter Veer E Haj Mohammad N van Valkenhoef G et al. The efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: a network meta-analysis. J Natl Cancer Inst. 2016; 108djw166 Crossref PubMed Scopus (84) Google Scholar Studies on the efficacy of combining chemotherapy with programmed death 1 (PD-1) inhibitors have changed the standard of care for these patients. 2 Lordick F Carneiro F Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33: 1005-1020 Summary Full Text Full Text PDF PubMed Scopus (112) Google Scholar In The Lancet, Kohei Shitara and colleagues 3 Shitara K Lordick F Bang Y-J et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023; (published online April 14.)https://doi.org/10.1016/S0140-6736(23)00620-7 Summary Full Text Full Text PDF PubMed Scopus (15) Google Scholar report the results of the phase 3 SPOTLIGHT trial, which investigated the effect of claudin-18 isoform 2 (CLDN18.2) targeting, using the monoclonal antibody zolbetuximab plus mFOLFOX6 (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen) in patients from 215 centres in 20 countries with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. CLDN18.2 is a tight junction protein that is specifically expressed in around 40% of HER2-negative adenocarcinomas of the upper gastrointestinal tract and has little expression elsewhere in the body, making it an attractive therapeutic target. 283 patients (median age 62·0 years, IQR 51·0–69·0; 176 [62%] men and 107 [38%] women; 88 [31%] from Asia and 195 [69%] from non-Asian regions) were randomly assigned to zolbetuximab (800 mg/m2 loading dose followed by 600 mg/m2 every 3 weeks) plus mFOLFOX6 (every 2 weeks). 282 patients (median age 60·0 years, 50·0–69·0; 175 (62%) men and 107 [38%] women; 89 [32%] from Asia and 193 [68%] from non-Asian regions) were randomly assigned to placebo. The primary endpoint was progression-free survival by independent review committee in all randomly assigned patients. The median progression-free survival was 10·61 months (95% CI 8·90–12·48) in the zolbetuximab group versus 8·67 months (8·21–10·28) in the placebo group (hazard ratio [HR] 0·75, 95% CI 0·60–0·94; p=0·0066). The median overall survival was 18·23 months (95% CI 16·43–22·90) in the zolbetuximab group versus 15·54 months (13·47–16·53) in the placebo group (HR 0·75, 95% CI 0·60–0·93; p=0·0053). Treatment-emergent grade 3 or worse adverse events occurred in 242 (87%) of 279 patients in the zolbetuximab group versus 216 (78%) of 278 patients in the placebo group. Treatment-related deaths occurred in five (2%) patients in the zolbetuximab group versus four (1%) patients in the placebo group. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialTargeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jay完成签到,获得积分10
刚刚
FashionBoy应助笑点低诗桃采纳,获得10
1秒前
1秒前
青柠完成签到,获得积分10
2秒前
258369发布了新的文献求助10
4秒前
Ava应助俏皮的白柏采纳,获得10
5秒前
James- LPY发布了新的文献求助10
6秒前
千余发布了新的文献求助10
9秒前
anan完成签到,获得积分10
9秒前
12秒前
12秒前
13秒前
14秒前
莹0000完成签到,获得积分10
15秒前
16秒前
YamDaamCaa应助科研通管家采纳,获得30
17秒前
YamDaamCaa应助科研通管家采纳,获得30
18秒前
桐桐应助科研通管家采纳,获得10
18秒前
18秒前
烟花应助科研通管家采纳,获得10
18秒前
星辰大海应助科研通管家采纳,获得10
18秒前
18秒前
moon发布了新的文献求助10
18秒前
幽默尔蓝发布了新的文献求助10
18秒前
默默的裘完成签到,获得积分10
20秒前
科研通AI2S应助liuzengzhang666采纳,获得10
21秒前
深情安青应助lll采纳,获得10
22秒前
闪闪完成签到,获得积分10
23秒前
AST灰烬发布了新的文献求助10
23秒前
24秒前
鲤跃发布了新的文献求助10
26秒前
27秒前
28秒前
情怀应助moon采纳,获得10
28秒前
28秒前
lll应助文件撤销了驳回
31秒前
31秒前
陈七七完成签到 ,获得积分10
32秒前
33秒前
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035